MX2015009155A - Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. - Google Patents

Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.

Info

Publication number
MX2015009155A
MX2015009155A MX2015009155A MX2015009155A MX2015009155A MX 2015009155 A MX2015009155 A MX 2015009155A MX 2015009155 A MX2015009155 A MX 2015009155A MX 2015009155 A MX2015009155 A MX 2015009155A MX 2015009155 A MX2015009155 A MX 2015009155A
Authority
MX
Mexico
Prior art keywords
alpha
acetylcholine receptor
nicotinic acetylcholine
receptor agonists
facilitation
Prior art date
Application number
MX2015009155A
Other languages
English (en)
Inventor
Dominik Feuerbach
Markus Fendt
Cristina Lopez-Lopez
Kevin Hall Mcallister
Judit Sovago
Markus Weiss
Donald Johns
Christer Halldin
Johannes Sjoerd Finnema
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015009155A publication Critical patent/MX2015009155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere al uso de cierto agonista del receptor nicotínico de acetilcolina alfa 7 para facilitar la recuperación de la anestesia general.
MX2015009155A 2013-01-15 2014-01-13 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. MX2015009155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361752772P 2013-01-15 2013-01-15
PCT/IB2014/058225 WO2014111838A1 (en) 2013-01-15 2014-01-13 Use of alpha 7 nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
MX2015009155A true MX2015009155A (es) 2016-03-04

Family

ID=50070639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009155A MX2015009155A (es) 2013-01-15 2014-01-13 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.

Country Status (10)

Country Link
EP (1) EP2945633B1 (es)
JP (1) JP6338223B2 (es)
KR (1) KR101879920B1 (es)
CN (1) CN105263495B (es)
BR (1) BR112015016995B8 (es)
CA (1) CA2898080C (es)
ES (1) ES2883232T3 (es)
MX (1) MX2015009155A (es)
TW (1) TWI633886B (es)
WO (1) WO2014111838A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661509A4 (en) * 2017-08-04 2021-01-13 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE SPLICE
AU2018372571A1 (en) * 2017-11-22 2020-07-02 The Governors Of The University Of Alberta Method of countering respiratory depression via activation of neuronal heteromeric nicotinic acetylcholine receptors
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
CN113677344A (zh) 2019-02-06 2021-11-19 斯基霍克疗法公司 用于调节剪接的方法和组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PL210065B1 (pl) 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
GB0412019D0 (en) 2004-05-28 2004-06-30 Novartis Ag Organic compounds
PE20060437A1 (es) * 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2008523058A (ja) 2004-12-10 2008-07-03 アボット・ラボラトリーズ 縮合ビシクロ複素環置換キヌクリジン誘導体
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
EP2018380B1 (en) 2006-05-19 2011-10-19 Abbott Laboratories Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN100448468C (zh) * 2006-11-14 2009-01-07 赵玉民 一种口服用于治疗胃病的药粉
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
JP5425915B2 (ja) 2008-10-13 2014-02-26 エフ．ホフマン−ラ ロシュ アーゲー 二環５−（トリフルオロメトキシ）−１ｈ−３−インダゾールカルボン酸アミドの合成におけるインダゾール中間体のジアゾニウムフリーの製造方法
JP5657556B2 (ja) * 2008-11-11 2015-01-21 ターガセプト，インコーポレイテッド α７選択的リガンドを用いる治療
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TWI558398B (zh) * 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
EP2637704B9 (en) * 2010-11-10 2015-08-05 H. Lundbeck A/S Radiolabelled phenylimidazole-based ligands
MX2013008704A (es) * 2011-01-27 2013-08-21 Novartis Ag Uso de activadores del receptor de acetil-colina nicotinico alfa-7.
KR20140027939A (ko) * 2011-06-30 2014-03-07 도레이 카부시키가이샤 지양제

Also Published As

Publication number Publication date
JP6338223B2 (ja) 2018-06-06
CN105263495B (zh) 2019-05-14
TW201440766A (zh) 2014-11-01
CN105263495A (zh) 2016-01-20
KR20150105469A (ko) 2015-09-16
ES2883232T3 (es) 2021-12-07
WO2014111838A1 (en) 2014-07-24
BR112015016995A2 (pt) 2017-07-11
EP2945633A1 (en) 2015-11-25
TWI633886B (zh) 2018-09-01
KR101879920B1 (ko) 2018-07-18
EP2945633B1 (en) 2021-06-30
BR112015016995B1 (pt) 2022-02-01
BR112015016995B8 (pt) 2022-07-26
JP2016509595A (ja) 2016-03-31
BR112015016995A8 (pt) 2018-01-23
CA2898080A1 (en) 2014-07-24
CA2898080C (en) 2018-01-09

Similar Documents

Publication Publication Date Title
ZA201904616B (en) Glp-1 receptor agonists and uses thereof
HK1257647A1 (zh) 使用fxr促效劑之方法
HK1257649A1 (zh) 使用fxr激動劑的方法
HK1255163A1 (zh) 作為apj受體激動劑的雜芳基羥基嘧啶酮
MX2017006320A (es) Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
ZA201807351B (en) Novel gpr119 agonist compounds
HK1257648A1 (zh) Fxr促效劑之使用方法
EP3718557A3 (en) Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
EP3160961A4 (en) Small molecule agonists of neurotensin receptor 1
MX2015009155A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
PH12018501844A1 (en) Liraglutide in cardiovascular conditions
MX2015009153A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
PL3019242T3 (pl) Kompozycje i sposoby leczenia zaburzeń neuropsychiatrycznych przy zastosowaniu agonisty receptora endoteliny-B
GB201619637D0 (en) C3a receptor agonists
IL264406B (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
GB201816747D0 (en) Linear apelin receptor agonists
TWM533512U (en) Shoulder pad for anesthesia
AU2015902112A0 (en) Agonists and antagonists for protease activated receptor 2 (PAR2)